Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Summary
Use in autoimmune disease is also supported by Centurys preclinical data demonstrating CNTY-101s ability to elicit more potent in vitro killing of B-cells from healthy donors and SLE patients as compared to primary CAR-T cells, as well as the encouraging initial safety, efficacy, and translational data from Centurys Phase 1 ELiPSE-1 trial in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).Century plans to evaluate CNTY-101 in moderate to severe SLE in the Phase 1 CALiPSO-1 trial ( ), the first autoimmune disease indication for its platform. Century has agreed to file a registration Statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement.The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the Minimum Price requirement (as defined in the Nasdaq rules).BofA Securities acted as the sole placement agent for the private placement made to institutional investors.This press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares offered in the private placement, nor shall there be any sale of such shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.The acquisition of Clade strengthens Centurys position as a leader in allogeneic, iPSC-derived cell therapy through the enhancement of its next generation platform including novel technology enhancing Centurys efforts on Allo-EvasionTM and a newly expanded pipeline incorporating three additional preclinical-stage programs from Clades iT platform spanning across cancer and autoimmune diseases. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune and inflammatory diseases. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune and inflammatory disease care. For more information on Century Therapeutics please visit .This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995.